MaxCyte, Inc.

What they do

MaxCyte sells the ExPERT family of instruments (DTx, ATx, STx, GTx, VLx) and related single-use processing assemblies and consumables, based on its Flow Electroporation technology. It also generates revenue from strategic platform licenses (SPLs) with biopharmaceutical companies, including milestone payments and commercial royalties. The company's customers range from top pharmaceutical companies to academic institutions, and its technology is used in ex vivo cell therapy manufacturing. It also provides assay services through its SeQure Dx acquisition.

Revenue drivers

• Instruments — Sales of ExPERT instruments; Q2 2026 revenue was $1.8 million, down 18% year-over-year.
• PAs and Consumables — Single-use processing assemblies and consumables used with instruments; Q2 2026 revenue was $2.3 million, down 25% year-over-year.
• Licenses — Includes SPL program-related revenue from milestones and royalties; Q2 2026 license revenue was $1.8 million, down 30%, while SPL program-related revenue was $0.8 million.
• Assay Service — Small but fast-growing, $0.2 million in Q2 2026, up 380% year-over-year.

Recent performance

Q2 2026 total revenue was $7.3 million, down 15% year-over-year, with core revenue of $6.5 million, down 21%. Net loss narrowed to $8.9 million from $12.4 million in the prior-year quarter. Operating expenses decreased to $15.8 million from $21.2 million. For the six months ended June 30, 2026, revenue was $9.4 million (Q1 $4.5M + Q2 $4.9M reported in financials; note earnings release shows Q2 total $7.3M, a discrepancy with XBRL figure). Cash, equivalents and investments were $141.9 million as of June 30, 2026.

Strategy

Management aims to return to revenue growth while reducing net losses, focusing on instrument placements and stability in PA sales. The company is expanding via strategic platform licenses, including a multi-platform license with Genentech announced in July 2026. It also acquired SeQure Dx in January 2025 to add gene editing assessment services. The board authorized a $10 million share repurchase program, with approximately $5.5 million repurchased to date.

Risks

• Revenue concentration and volatility — Relies on a limited number of customers and instrument sales, which have long sales cycles and quarterly fluctuations.
• Dependence on SPL partners — SPL program-related revenue depends on partner progress through clinical development, which is outside MaxCyte's control.
• Ongoing losses and capital needs — Net losses and negative operating cash flow continue (net loss $44.6M in 2025; operating cash flow -$34.4M), with no near-term profitability expected.
• Manufacturing and supply chain risks — Depends on third-party suppliers for instrument components and raw materials; limited experience in high-volume PA manufacturing.

Outlook

For full year 2026, management guides total revenue of $30 million to $32 million, with core revenue of $25 million to $27 million and SPL program-related revenue of approximately $5 million ($3 million from milestones, $2 million from royalties). The company expects to end 2026 with at least $130.5 million in total cash, equivalents and investments, excluding further share repurchases. It reiterated this guidance in the Q2 earnings release.